These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 1735737

  • 1. Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy.
    Markman M, Jones W, Lewis JL, Rubin S, Hakes T, Reichman B, Barakat R, Curtin J, Almadrones L, Hoskins W.
    J Cancer Res Clin Oncol; 1992; 118(2):163-5. PubMed ID: 1735737
    [Abstract] [Full Text] [Related]

  • 2. Salvage intraperitoneal therapy of advanced epithelial ovarian cancer: impact of retroperitoneal nodal disease.
    Barakat RR, Fennelly D, Pizzuto F, Venkatraman ES, Brown C, Curtin JP.
    Eur J Gynaecol Oncol; 1997; 18(3):161-3. PubMed ID: 9174826
    [Abstract] [Full Text] [Related]

  • 3. Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate.
    Markman M, Reichman B, Hakes T, Barakat R, Curtin J, Rubin S, Jones W, Lewis JL, Almadrones L, Hoskins W.
    J Cancer Res Clin Oncol; 1992; 118(3):235-7. PubMed ID: 1548290
    [Abstract] [Full Text] [Related]

  • 4. Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
    Markman M, Reichman B, Hakes T, Rubin S, Lewis JL, Jones W, Barakat R, Curtin J, Almadrones L, Hoskins W.
    Gynecol Oncol; 1993 Jul; 50(1):100-4. PubMed ID: 8349150
    [Abstract] [Full Text] [Related]

  • 5. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.
    Markman M, Reichman B, Hakes T, Jones W, Lewis JL, Rubin S, Almadrones L, Hoskins W.
    J Clin Oncol; 1991 Oct; 9(10):1801-5. PubMed ID: 1919630
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer.
    Piver MS, Recio FO, Baker TR, Driscoll D.
    Cancer; 1994 Mar 15; 73(6):1693-8. PubMed ID: 7512437
    [Abstract] [Full Text] [Related]

  • 12. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C, Louvet C, Molitor JL, Dehni N, Lejeune V, Sezeur A, Pigne A, Marpeau L, Cady J, de Gramont A.
    Gynecol Oncol; 2001 Nov 15; 83(2):198-204. PubMed ID: 11606072
    [Abstract] [Full Text] [Related]

  • 13. First experiences with intraperitoneal chemotherapy in ovarian cancer.
    Gitsch E, Sevelda P, Schmidl S, Salzer H.
    Eur J Gynaecol Oncol; 1990 Nov 15; 11(1):19-22. PubMed ID: 2347331
    [Abstract] [Full Text] [Related]

  • 14. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
    Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis JL.
    J Clin Oncol; 1991 Mar 15; 9(3):389-93. PubMed ID: 1999708
    [Abstract] [Full Text] [Related]

  • 15. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
    Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Jones W, Almadrones L, Ochoa M, Chapman D, Saigo P.
    J Clin Oncol; 1989 Sep 15; 7(9):1327-32. PubMed ID: 2671288
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
    Braly PS, Berek JS, Blessing JA, Homesley HD, Averette H.
    Gynecol Oncol; 1995 Feb 15; 56(2):164-8. PubMed ID: 7896179
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
    Husain A, Sabbatini P, Spriggs D, Fennelly D, Aghajanian C, Barakat R, Curtin J, Venkatraman E, Hoskins W, Markman M.
    Gynecol Oncol; 1999 Apr 15; 73(1):96-101. PubMed ID: 10094887
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.